We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

ThromboGenics and BioInvent Announce Results from Phase IIb VTE Prevention Study with TB-402

News   Jul 05, 2012

 
ThromboGenics and BioInvent Announce Results from Phase IIb VTE Prevention Study with TB-402
 
 
 

RELATED ARTICLES

Japan Approves Stem Cell Therapy for Spinal Cord Injuries

News

A stem cell therapy has been given the green light for the treatment of spinal cord injuries, and a follow-up trial is set to begin later this year. However, independent researchers warn that the approval is premature.

READ MORE

Multi-organ "Human-on-a-Chip" Enables Long-term Toxicology Testing

News

The microfluidic device with interlinking modules containing human-derived heart, liver, skeletal muscle and nervous system cells was able to maintain cellular viability and record cellular function in real-time for 28 days.

READ MORE

Antibody Therapy That Trains Phagocytes to Destroy Tumors Is Tested in Patients

News

An immunotherapeutic antibody therapy re-educates macrophages to activate passivated cytotoxic T cells to kill cancer. The antibody therapy prevented the growth of tumors in several mouse models. The development of the therapy has now progressed to patient testing in a phase I/II clinical trial.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE